Eva Ellebæk

Medicine & Life Sciences

1. Melanoma 100%
2. Tumor-Infiltrating Lymphocytes 27%
3. Survival 21%
4. Immunotherapy 21%
5. Dendritic Cells 20%
6. Nivolumab 19%
7. Cell- and Tissue-Based Therapy 19%
8. Vaccination 18%
9. T-Lymphocytes 17%
10. Therapeutics 16%
11. Indoleamine-Pyrrole 2,3,-Dioxygenase 14%
12. Denmark 11%
13. Neoplasms 11%
14. Interleukin-2 11%
15. Cyclophosphamide 9%
16. Recurrence 9%
17. Phosphatidylethanolamine Binding Protein 8%
18. Antigens 8%
19. Ipilimumab 8%
20. tofacitinib 8%
21. Proto-Oncogene Proteins c-raf 7%
22. Adoptive Transfer 7%
23. Cancer Vaccines 7%
24. Fecal Microbiota Transplantation 7%
25. T-Cell Antigen Receptor Specificity 7%
26. Clinical Trials 7%
27. Enterocolitis 7%
28. Cohort Studies 7%
29. Combined Vaccines 7%
30. Vaccines 6%
31. Uveal melanoma 6%
32. Mitogen-Activated Protein Kinase Kinases 6%
33. Positron Emission Tomography Computed Tomography 6%
34. Databases 6%
35. Synthetic Vaccines 6%
36. Enteritis 6%
37. Subunit Vaccines 6%
38. Epitopes 6%
39. Confidence Intervals 6%
40. Population 5%
41. Cardiotoxicity 5%
42. Translational Medical Research 5%
43. Docetaxel 5%
44. Castration 5%
45. Progression-Free Survival 5%
46. Colitis 5%
47. Skin 5%
48. Neoplasm Antigens 5%